Mitochondrial permeability transition pore as a suitable target for neuroprotective agents against alzheimer’s disease

CNS and Neurological Disorders - Drug Targets

Volumn 16, Issue 6, 2017, Pages 677-685

  Shevtsova, Elena F ^a   Vinogradova, Daria V ^a   Neganova, Margarita E ^a   Avila Rodriguez, Marco ^b,c   Ashraf, Ghulam Md ^d   Barreto, George E ^b,e   Bachurin, Sergey O ^a   Aliev, Gjumrakch ^a,f,g  

^a INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c UNIVERSIDAD DEL TOLIMA   (Colombia)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^f GALLY International Biomedical Research Consulting LLC   (United States)

^g University of Atlanta   (United States)

Author keywords

Alzheimer's disease; Mitochondria; Mitochondrial dysfunction; Multitarget benefits; Neurodegenerative diseases; Neuroprotective

Indexed keywords

ALISPORIVIR; AMIDE; AMYLOID BETA PROTEIN; AZASTEROID; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DIMEBON; MELATONIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N ACETYLSEROTONIN; NEUROPROTECTIVE AGENT; PILOCARPINE; SECURININE; TRYPTAMINE; CARRIER PROTEIN;

ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CELL FUNCTION; CELL ORGANELLE; COGNITION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METABOLIC BALANCE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR INTERACTION; NERVE DEGENERATION; NERVE STIMULATION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PROTEIN TARGETING; SEIZURE; SYSTEMATIC REVIEW; ANIMAL; DRUG EFFECT; MITOCHONDRION; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; NEUROPROTECTIVE AGENTS;

EID: 85029634459     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527316666170424114444     Document Type: Article

References (104)

1. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11(2): 111-28.
2. Swerdlow RH, Burns JM, Khan SM. The alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives. Biochimica et Biophysica Acta 2014; 1842(8): 1219-31.
3. Shevtzova EF, Kireeva EG, Bachurin SO. Effect of beta-amyloid peptide fragment 25-35 on nonselective permeability of mitochondria. Bull Exp Biol Med 2001; 132(6): 1173-76.
4. Eckert A, Schmitt K, Gotz J. Mitochondrial dysfunction -the beginning of the end in Alzheimer’s disease? Separate and synergistic modes of tau and amyloid-β toxicity. Alzheimers Res Ther 2011; 3(2): 15.
5. Harman D. A hypothesis on the pathogenesis of Alzheimer’s disease. Ann NY Acad Sci 1996; 786: 152-68.
6. Caspersen C, Wang N, Yao J, et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J 2005; 19(14): 2040-1.
7. Kumar A, Bodhinathan K, Foster TC. Susceptibility to calcium dysregulation during brain aging. Front Aging Neurosci 2009; 1: 2.
8. Oh MM, Oliveira FA, Waters J, Disterhoft JF. Altered calcium metabolism in aging ca1 hippocampal pyramidal neurons. J Neurosci 2013; 33(18): 7905-11
9. Mattson MP. Calcium and neurodegeneration. Aging Cell 2007; 6(3): 337-50
10. Lopez JR, Lyckman A, Oddo S, Laferla FM, Querfurth HW, Shtifman A. Increased intraneuronal resting [Ca2+] in adult Alzheimer’s disease mice. J Neurochem 2008; 105(1): 262-71.
11. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341: 233-49.
12. Peng T, Jou M. Oxidative stress caused by mitochondrial calcium overload. Ann N Y Acad Sci 2010; 1201: 183-8.
13. Rapizzi E, Pinton P, Szabadkai G, et al. Recombinant expression of the voltage-dependent anion channel enhances the transfer of Ca2+ microdomains to mitochondria. J Cell Biol 2002; 159(4): 613-24.
14. Giacomello M, Drago I, Pizzo P, Pozzan T. Mitochondrial Ca2+ as a key regulator of cell life and death. Cell Death Differ 2007; 14(7): 1267-74.
15. Velikanov GA. Endoplasmic reticulum: membrane contact sites. Cell Tiss Biol 2013; 7: 504.
16. Bae TJ, Kim MS, Kim JW, et al. Lipid raft proteome reveals ATP synthase complex in the cell surface. Proteomics 2004; 4 (11): 3536-48.
17. Moser TL, Kenan DJ, Ashley TA, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci 2001; 98(12): 6656-61.
18. Yonally SK, Capaldi RA. The F1F0 ATP synthase and mitochondrial respiratory chain complexes are present on the plasma membrane of an osteosarcoma cell line: an immunocytochemical study. Mitochondrion 2006; 6(6): 305-14.
19. Gingrich JR, Pelkey KA, Fam SR et al. Unique domain anchoring of Src to synaptic NMDA receptors via the mitochondrial protein NADH dehydrogenase subunit 2. Proc Natl Acad Sci 2004; 101: 6237-41.
20. Shevtsova EP, Dubova LG, Kireeva EG, Bachurin SO. Mitochondria as the memantine target. European Neuropsychopharmacology 2006; 16: 243-4.
21. Korde AS, Maragos WF. Identification of an N-methyl-D-aspartate receptor in isolated nervous system mitochondria. J Biol Chem 2012; 287(42): 35192-200.
22. Barsukova A, Komarov A, Hajnoczky G, Bernardi P, Bourdette D, Forte M. Activation of the mitochondrial permeability transition pore modulates Ca2+ responses to physiological stimuli in adult neurons. Eur J Neurosci 2011; 33(5): 831-42.
23. Bernardi P. The mitochondrial permeability transition pore: a mystery solved? Front Physiol Frontiers 2013; 4: 95.
24. Weeber EJ, Levy M, Sampson MJ, et al. The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J Biol Chem 2002; 277(21): 18891-7.
25. Skulachev VP. Mitochondria-targeted antioxidants as promising drugs for treatment of age-related brain diseases. J Alzheimers Dis 2012; 28 (2): 283-9.
26. Pavlov E, Zakharian E, Bladen C, et al. A large, voltage-dependent channel, isolated from mitochondria by water-free chloroform extraction. Biophys J 2005; 88(4): 2614-25.
27. Abramov AY, Fraley C, Diao CT, et al. Targeted polyphosphatase expression alters mitochondrial metabolism and inhibits calciumdependent cell death. Proc Natl Acad Sci 104(46); 18091-6.
28. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341: 233-49.
29. Kokoszka JE, Waymire KG, Levy SE, et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004; 427(6973): 461-5.
30. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrialdependent cell death. Nat Cell Biol 2007; 9(5): 550-5.
31. Varanyuwatana P, Halestrap AP. The roles of phosphate and the phosphate carrier in the mitochondrial permeability transition pore. Mitochondrion 2012; 12: 120-5.
32. Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27(8): 402-9.
33. Roestenberg P, Manjeri GR, Valsecchi F, Smeitink JAM, Willems PHGM, Koopman WJH. Pharmacological targeting of mitochondrial complex I deficiency: the cellular level and beyond. Mitochondrion 2012; 12(1): 57-65.
34. Bonora M, Bononi A, De Marchi E, et al. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. Cell Cycle 2013; 12(4): 674-83.
35. Kowaltowski AJ, Castilho RF, Vercesi AE. Mitochondrial permeability transition and oxidative stress. FEBS Lett 2001; 495(1-2): 12-5.
36. He L, Lemasters JJ. Regulated and unregulated mitochondrial permeability transition pores: A new paradigm of pore structure and function? FEBS Lett 2002; 512(1-3): 1-7.
37. Merlini L, Sabatelli P, Armaroli A et al. Cyclosporine A in Ullrich Congenital Muscular Dystrophy: Long-Term Results. Oxidative Medicine and Cellular Longevity 2011; 2011: 1-10
38. Nighoghossian N, Berthezene Y, Mechtouff L, et al. Cyclosporine in acute ischemic stroke. Neurology 2015; 84(22): 2216-23.
39. Atkinson K, Britton K, Biggs J. Distribution and concentration of cyclosporin in human blood. J Clin Pathology 1984; 37(10): 1167-71.
40. Waldmeier PC, Feldtrauer JJ, Qian T, Lemasters JJ. Inhibition of the mitochondrial permeability transition by the nonimmunosup pressive cyclosporin derivative NIM811. Mol Pharmacol 2002; 62(1): 22-9.
41. Readnower RD, Pandya JD, McEwen ML, Pauly JR, Springer JE, Sullivan PG. Post-injury administration of the mitochondrial permeability transition pore inhibitor, NIM811, is neuroprotective and improves cognition after traumatic brain injury in rats. J Neurotrauma 2011; 28(9): 1845-3.
42. Hokari M, Kuroda S, Iwasaki Y. Pretreatment with the cyclosporin derivative nim811 reduces delayed neuronal death in the hippocampus after transient forebrain ischaemia. J Pharm Pharmacol 2010; 62: 485-49.
43. Korde AS, Pettigrew LC, Craddock SD, Pocernich CB, Waldmeier PC, Maragos WF. Protective effects of NIM811 in transient focal cerebral ischemia suggest involvement of the mitochondrial permeability transition. J Neurotrauma 2007; 24: 895-908.
44. Wissing ER, Millay DP, Vuagniaux G, Molkentin JD. Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice. Neuromuscul Disord 2010; 20: 753-60.
45. Nowikovsky K, Schweyen RJ, Bernardi P. Pathophysiology of mitochondrial volume homeostasis: potassium transport and permeability transition. Biochim Biophys Acta 2009; 1787(5): 345-50.
46. Warne J, Pryce G, Hill JM, et al. Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis. J Biol Chem 2016; 291(9): 4356-73.
47. Roy S, Šileikytė J, Schiavone M, et al. Discovery, synthesis, and optimization of diarylisoxazole-3-carboxamides as potent inhibitors of the mitochondrial permeability transition pore. Chem Med Chem 2015; 10(10): 1655-71.
48. Averina EB, Vasilenkova DA, Gracheva YA, et al. Synthesis and biological evaluation of novel 5-hydroxylaminoisoxazole derivatives as lipoxygenase inhibitors and metabolism enhancing agents. Bioorg Med Chem 2016; 24(4): 712.
49. Smith RA, Adlam VJ, Blaikie FH, et al. Mitochondria-targeted antioxidants in the treatment of disease. Ann N Y Acad Sci 2008; 1147: 105-11.
50. Rocha M, Hernandez-Mijares A, Garcia-Malpartida K, Banuls C, Bellod L, Victor VM. Mitochondria-targeted antioxidant peptides. Curr Pharm Des 2010; 16(28): 3124-31.
51. Srinivasan V, Spence DW, Pandi-Perumal SR, Brown GM, Cardinali DP. Melatonin in mitochondrial dysfunction and related disorders. international j alzheimer’s disease 2011; 2011: 1-16.
52. He H, Dong W, Huang F. Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. Curr Neuropharmacol 2010; 8(3): 211-7.
53. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 2009; 15(4): 345-57.
54. Pandi-Perumal SR, BaHammam AS, Brown GM, et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res 2013; 23(3): 267-300.
55. Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 2004; 18(7): 869-71.
56. Bachurin S, Oxenkrug G, Lermontova N, et al. N-Acetyl-serotonin, melatonin and their derivatives improve cognition and protect against beta-amyloid-induced neurotoxicity. Annals of NY Aca of Sci 2000; 890: 156-66.
57. Zhou H, Wang J, Jiang J, et al. N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury. J Neurosci 2014; 34(8): 2967-78.
58. Wang X, Figueroa BE, Stavrovskaya IG, et al. Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke 2009; 40(5): 1877-85.
59. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003; 993: 334-44.
60. Millan-Plano S., Piedrafita E, Miana-Mena FJ, Fuentes-Broto L. et al. Melatonin and structurally-related compounds protect synaptosomal membranes from free radical damage. Int J Mol Sci 2010; 11: 312-28.
61. Neganova ME, Klochkov SG, Afanasieva SV, Chudinova ES, Serkova TP, Shevtsova EF. Allomargaritarine as a basis for the creation of mitochondrial targeted potential neuroprotectors. Eur Neuropsychopharmacol 2014; 24: 262.
62. Aleshkina IA, Turova AD. To pharmacology of new alkaloid securinine. Pharmakol Toxicol 1956; 19: 11-7.
63. Beutler JA, Karbon EW, Brubaker AN, Malik R, Curtis DR, Enna SJ. Securinine alkaloids: a new class of GABA receptor antagonist. Brain Res 1985; 330: 135-40.
64. Raj D, Luczkiewicz M. Securinega suffruticosa. Fitoterapia 2008; 79(6): 419-27.
65. Copperman R, Copperman G, Der Marderosian A. From Asia securinine-a central nervous stimulant is used in treatment of amytrophic lateral sclerosis. Pa Med 1973; 76: 36-41.
66. Lin X, Jun-Tian Z. Neuroprotection by D-securinine against neurotoxicity induced by beta-amyloid (25-35). Neurol Res 2004; 26(7): 792-6.
67. Neganova ME, Serkova TP, Klochkov SG, Afanasieva SV, Shevtsova EF, Bachurin SO. Neuroprotective properties of Allomargaritarine, a novel tryptamine derivative of the natural alkaloid securinine. Nat Tech Sci 2011; 5: 86-90.
68. Neganova ME, Klochkov SG, Afanasieva SV, Chudinova ES, Serkova TP, Shevtsova EF. Allomargaritarine as a basis for the creation of mitochondrial targeted potential neuroprotectors. Eur Neuropsychopharmacol 2014; 24: 262.
69. Neganova ME, Klochkov SG, Afanasieva SV, et al. Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound. CNS Neurol Disord Drug Targets 2016; 15: 102-7.
70. Neganova ME, Klochkov SG, Petrova LN, et al. Securinine derivatives as potential anti-amyloid therapeutic approach. CNS Neurol Disord Drug Targets 2016 [Epub ahead of print].
71. Neganova ME, Blik VA, Klochkov SG, Chepurnova NE, Shevtsova EF. Investigation of the antioxidant characteristics of a new tryptamine derivative of securinine and its influence on seizure activity in the brain in experimental epilepsy. Neurochemical J 2011; 5: 208.
72. Kim do Y., Simeone KA, Simeone TA, et al. Ketone bodies mediate antiseizure effects through mitochondrial permeability transition. Ann Neurol 2015; 78(1): 77-87.
73. Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz WS. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 2004; 45(12): 1478-87.
74. Matveeva IA. [Action of dimebon on histamine receptors]. Pharm Toxicology 1983; 46(4): 27-9.
75. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 2003; 993: 334-44.
76. Shevtsova EF, Vinogradova DV, Kireeva EG, V. Prakash Reddy, Aliev G, Bachurin SO. Dimebon Attenuates the Rat-Brain Mitochondrial Permeabilization. Curr Alzheimer Res 2015; 11(5): 422-9.
77. Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis 2010; 21(2): 389-402.
78. Bharadwaj PR, Verdile G, Barr RK et al. Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. J Alzheimers Dis 2012; 32(4): 949-67.
79. Eckert SH, Eckmann J, Renner K, Eckert GP, Leuner K, Muller WE. Dimebon ameliorates amyloid-β induced impairments of mitochondrial form and function. J Alzheimers Dis 2012; 31(1): 21-32.
80. Bachurin SO, Grigoriev V, Shevtsova E, Koroleva I, Dubova L, Kireeva E. Anti-aging properties of Dimebon: relation to mitochondrial permeability inhibition. Exp Gerontology 2007; 42(1-2): 142-3.
81. Peters OM, Shelkovnikova T, Tarasova T et al. Chronic administration of Dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice. J Alzheimers Dis 2013; 36(3): 589-96.
82. Peters OM, Connor-Robson N, Sokolov VB et al. Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. J Alzheimers Dis 2013; 33(4): 1041-9.
83. Bachurin SO, Shelkovnikova TA, Ustyugov AA et al. Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice. Neurotox Res 2012; 22(1): 33-42.
84. Ustyugov AA, Shelkovnikova TA, Kokhan VS et al. Dimebon reduces the levels of aggregated amyloidogenic protein forms in detergent-insoluble fractions in vivo. Bull Exp Biol Med 2012; 152(6): 731-3.
85. Yamashita M, Nonaka T, Arai T et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 2009; 583(14): 2419-24.
86. Steele JW, Gandy S. Latrepirdine (DimebonR), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy 2013; 9(4): 617-8.
87. Khritankova IV, Kukharskiy MS, Lytkina OA, Bachurin SO, Shorning BY. Dimebon activates autophagosome components in human neuroblastoma SH-SY5Y cells. Dokl Biochem Biophys 2012; 446: 251-3.
88. Bharadwaj PR, Verdile G, Barr RK et al. Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. J Alzheimers Dis 2012; 32(4): 949-67.
89. Šoškić V, Klemm M, Proikas-Cezanne T et al. A connection between the mitochondrial permeability transition pore, autophagy, and cerebral amyloidogenesis. J Proteome Res 2008; 7(6): 2262-69.
90. Lemasters JL, Nieminen AL, Qian T et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochimica et Biophysica Acta (BBA) -Bioenergetics 1998; 1366(1-2): 177-96.
91. Pieper AA, Xie S, Capota E et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010; 142(1): 39-51.
92. Pieper AA, Xie S, Capota E et al. Discovery of a pro-neurogenic, neuroprotective chemical. Cell 2010; 142(1): 39-51.
93. Hou Y, Mattson MP, Cheng A. Permeability transition poremediated mitochondrial superoxide flashes regulate cortical neural progenitor differentiation. PLoS ONE 2013; 8(10): 76721.
94. Shin JY, Kong SY, Yoon HJ, Ann J, Lee J, Kim HJ. An aminopropyl carbazole derivative induces neurogenesis by increasing final cell division in neural stem cells. Biomol Ther (Seoul) 2015; 23(4): 313-9.
95. Wang G, Han T, Nijhawan D et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 2014; 158(6): 1324-34.
96. Wang SN, Xu TY, Wang X et al. Neuroprotective efficacy of an aminopropyl carbazole derivative p7c3-a20 in ischemic stroke. CNS Neurosci Ther 2016; 22(9): 782-8.
97. Jiang B, Song L, Huang C, Zhang W. P7C3 attenuates the scopolamine-induced memory impairments in C57BL/6J mice. Neurochem Res 2016; 41(5): 1010-9.
98. Walker AK, Rivera PD, Wang Q et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry 2015; 20(4): 500-8.
99. De Jesus-Cortes H, Miller AD, Britt JK et al. Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease. NPJ Parkinsons Dis 2015; 1:15010.
100. Blaya MO, Bramlett HM, Naidoo J, Pieper AA, Dietrich WD. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury. J Neurotrauma 2014; 31(5): 476-86.
101. De Jesus-Cortes H, Xu P, Drawbridge J et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci 2012; 109(42): 17010-5.
102. Tesla R, Wolf HP, Xu P et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci 2012; 109(42): 17016-21.
103. Kuharskiy MS, Ovchinnikov RK, Ustyugov AA, Bachurin SO. Molecular aspects of pathogenesis and modern appoaches to pharmacological correction of alzheimer's disease. In: MV ugryumov, ed.; neurodegenerative diseases: from the genome to the whole organism. Sci World 2014; 2: 137-162.
104. Bachurin SO. Contemporary approaches for pharmacological intervention of abundant neurodegenerative disorders. J Nanomedine Biotherapeutic Discov 2015; 5(2): 137.